期刊文献+

人血浆中盐酸多奈哌齐的HPLC-MS测定法(英文) 被引量:5

Quantitation of Donepezil in Human Plasma by HPLC-MS
下载PDF
导出
摘要 目的 :建立人血浆中盐酸多奈哌齐的HPLC MS法。方法 :血样经饱和NaHCO3 碱化后用乙酸乙酯提取 ,进行HPLC MS分析 ,色谱柱为HypersilODS(5μm ,2 50mm× 4 6mm) ,流动相为甲醇 水 三乙胺 冰醋酸 (70∶3 0∶0 3∶0 3 ) ,内标为盐酸非洛普 ,检测离子为m /z 3 80 (多奈哌齐 )、m/z 3 4 4 (内标 ) ,裂解电压为 12 0V。结果 :在 0 2~ 2 0ng/ml范围内多奈哌齐与内标峰面积比值与浓度线性关系良好 (r =0 9996) ,最低可定量浓度为 0 1ng/ml,提取回收率为 87 52 %~ 90 91%。结论 :本实验建立的分析方法灵敏、准确。 AIM and METHOD:A highly sensitive method for quantita tion of donepezil in human plasma was established by using liquid chromatography -electrospray ionization-mass spectrometry (LC-ESI-MS), with phenoprolamine hydrochloride as the internal standard (I.S. ). After alkalizing with saturated sodium bicarbonate, plasma was extracted with e thyl acetate and the extracts were separated by HPLC on a C 18 reversed-ph ase c olumn with methanol-water-acetic acid-triethylamine (70∶30∶03∶03,v/ v ) as mobile phase. LC-ESI-MS was performed in the selected ion monitoring (S IM) mode us in g target ions at m/z 380 for donepezil and m/z 344 for the I.S..RE SULT:Calibra tion curves, which were linear over the range of 02 to 20 ng/ml, were establis hed contemporaneously with the analyses of each batch of samples, along with low (0 2 ng/ml), medium (2 ng/ml) and high (20 ng/ml) quality control samples. The in tra a nd inter-assay variability ranged from 125% to 984% for the low, medium and hig h quality control samples. The extraction recovery of donepezil from plasma was in the range of 875%~919%.CONCLUSION:The method has been us ed successfully to study donepezil pharmacokinetics in human plasma.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2004年第1期36-39,共4页 Journal of China Pharmaceutical University
关键词 盐酸多奈哌齐 HPLC-MS 血浆 含量测定 Donepezil HPLC-MS Human plasma Determi nation of content
  • 相关文献

参考文献4

  • 1[1]Yamanishi Y,Ogura H,Kosasa T,et al.Clinical and therapeutic aspect of alzheimer's and parkinson' diseases [ J ].Plenum Press,1990,(2):409.
  • 2[2]Rogers SL,Yamanishi Y,Yamatsu K.Cholinergic basis for alzheimer therapy[M].Boston:Birkhauser,1991.314.
  • 3[3]Ohnishi A,Mihara M,Kamakura H,et al.Comparison of the pharmacokinetics of E2020,a new compound for Alzheimer's disease,in healthy young and elderly subjects[J].J Clin Pharmacol,1993(33):1086-1090.
  • 4[4]Matsui K,Oda Y,Ohe H,et al.Direct determination of E2020 enantiomersin plasma by liquid chromatography-mass spectrometry and columm-swithing[ J].J Chromatogr A,1995( 694 ):209.

同被引文献21

  • 1董瑞谦,王本杰,郭瑞臣.盐酸多奈哌齐片人体生物等效性研究[J].中国现代应用药学,2004,21(4):293-295. 被引量:5
  • 2马武翔,黄立萍.固相萃取反相高效液相色谱法测定人血浆中多奈哌齐浓度[J].中国医院药学杂志,2006,26(2):149-151. 被引量:6
  • 3陆益红,张玫,孟群,张正行.毛细管电泳法分离测定血浆样品中盐酸多奈哌齐对映体[J].药学学报,2006,41(5):471-475. 被引量:5
  • 4Rho J P, l.ipson L G. Focus on donepezil : a reversible acetyleholinesterase inhibitor for the treatment of Alzheimer' s disease [J]. Formulary,1997,32:677-678.
  • 5Mihara M, Ohnishi A, Tomono Y, et al. Pharmacokinetics of E2020. a new compound for Alzheimer's disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol, 1993,31 (5) :223.
  • 6Rho JP, Lipson LG. Focus on donepezil:a reversible acetvlcholinest-erase inhibitor for the treatment of Alzheimer's disease. Formulary, 1997,32 (7) :677.
  • 7Rogers SL,Doody RS,Mohs RC,et ol. Donepezil improves cognition and global function in Alzheimer disease :a 15 - week,double - blind,placebo - controlled study. Awh Intern Med, 1998,158 (9) : 1021.
  • 8Authorized USP pending Standard Version 1. 2008:1 [2008 - 01 - 28].
  • 9Homing EC. Orgnic. Syntheses Collecpive Vol III. NewYork :John Wi- ley, 1955. 140.
  • 10Mihara M,Ohnishi A,Tomono Y,et al Pharmacokinetics of E2020,a new compound for Alzheimer's disease,in healthy male volunteers[J].Int J Clin Pharmacol Ther Toxicol,1993;31:223-229.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部